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ABSTRACT
Background: In the present study, we measured
specific IgE radioallergosorbent test (RAST) levels for
house dust, mites, Japanese cedar, kamogaya
(Dactylis glomerata) and ragweed antigens in a group
of atopic dermatitis (AD) patients and healthy vol-
unteer subjects in our outpatient clinic. We also
performed closed patch testing with patch test re-
agents using the aforementioned antigens prepared
from commercially available skin reaction antigens.
Methods: The dermatologic symptom severity index,
duration of disease, total serum IgE, lactate dehydro-
genase (LDH) and eosinophil counts were assessed.
The relationship between each of these parameters
and the intensity of the response to the patch test was
then evaluated.
Results: The patch test positivity rate increased in pro-
portion with the duration of antigen application, with a
maximum of 15.6% for mite antigen and a minimum of
4.7% for cedar antigen by 72 h. There were no antigens
showing negative results in any patients. The positivity
rate was lower for patch tests applied on highly kera-
tinized areas of skin. The 72 h positive patch test
responses were significantly correlated with total serum
IgE, LDH, symptom severity index and specific IgE RAST
levels. Most positive patch test responses were consid-
ered to be possible late phase reactions of the type I
allergic response. However, a small number of patients
had IgE RAST negative antigens but positive patch tests.
Conclusions: These findings suggest the presence of
more than one mechanism by which a positive reac-
tion is elicited.
Key words: atopic dermatitis, late phase reaction,
patch testing.
INTRODUCTION
Some atopic dermatitis (AD) patients have positive patch
tests for environmental antigens. This serves as a basis 
for theories emphasizing the role of type IV allergic
responses in AD.1–3 However, many patients with positive
patch tests also have antigen-specific IgE antibodies,
immediate intradermal reactions and positive scratch
tests.2,4 This lends support to theories that implicate type I
allergic responses.
In 1986, Bruynzeel-Koomen et al. confirmed the pres-
ence of IgE antibodies on intra-epidermal Langerhans’
cells5 and Tanaka et al. described transepidermal inva-
sion of mite antigens that bind to these antibodies.6 Since
then, many investigators have postulated that trans-
epidermal invasion of environmental antigens plays some
role in inflammation in the skin, which, in turn, acts as an
exacerbating factor in AD. Thus, patch testing has become
an important diagnostic study. However, the lack of com-
mercially available patch test antigens in Japan has been
one obstacle in diagnosing patients with AD.7 The objec-
tive of the present study was to evaluate the relationship
between patch test responses and levels of various antigen-
specific IgE. The patch test reagents were prepared from
commercially available intradermal solutions containing
environmental antigens for diagnostic and therapeutic
use. Symptom severity index, duration of disease, total
serum IgE, lactate dehydrogenase (LDH) and eosinophil
counts were also assessed. We then evaluated the rela-
tionship between these clinical parameters and patch test
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responses in order to investigate the overall significance
of patch testing in the diagnosis of AD.
METHODS
Subjects
This study enrolled a total of 64 AD patients who were
evaluated in our outpatient department. A diagnosis of
AD was based on evaluation criteria established by 
the Japanese Dermatological Association.8 The study
included 33 men and 31 women, ranging in age from 16
to 48 years (mean age 28 years). In addition, a total of
10 healthy volunteers without subjective symptoms or
objective findings of disease were enrolled in the study as
control subjects. This group consisted of six men and four
women, ranging in age from 29 to 63 years (mean age
38 years). There was no restriction with respect to
antigen-specific IgE levels at the time of enrollment.
Preparation of patch test reagents
Allergen extracts for diagnostic, therapeutic and scratch
tests were purchased from Torii Pharmaceuticals (Tokyo,
Japan). These extracts included house dust (therapeutic
use; 1%), Dermatophagoides farinae (scratch test extract;
1%), cedar (therapeutic use; 1%), kamogaya (diagnostic
use; 5%), and ragweed (therapeutic use; 1%). Each extract
solution was added to white Vaseline (Yoshida Pharma-
ceutical, Tokyo, Japan) containing 0.1% sodium lauryl
sulfate to prepare 0.5% antigen concentrations. These
were mixed in a mortar and emulsified. The above allergen
extracts (with the exception of house dust extract) contained
50% glycerin. The final glycerin concentration in the pre-
pared reagents was 25%. There were three types of control
reagents: (i) white Vaseline; (ii) white Vaseline containing
0.1% sodium lauryl sulfate; and (iii) white Vaseline con-
taining 0.1% sodium lauryl sulfate and 25% glycerin.
Patch testing
The patch test reagents were applied using a Finn-
chamber® (Epitest, Tuusula, Finland) for 24 and 48 h to
the medial aspect of the upper arm (rash-free areas) and
results were evaluated after 24, 48 and 72 h from the
start of application. Test results were evaluated in accor-
dance with International Contact Dermatitis Research
Group (ICDRG) criteria.9 In some subjects, reagents were
applied to the medial aspect of the thigh (rash-free areas)
for 48 h to compare differences with respect to patch test
site and results were evaluated after 72 h from the start 
of application.
Clinical parameters
The following clinical parameters were investigated in the
present study.
1. Duration of disease. This was estimated by examining
patients’ medical histories.
2. Severity index. This was estimated using a partially
modified method of Yoshiike et al.10 Estimations were
based on total numerical values, excluding pruritus
scores because of difficulties in subjective assessment
(Table 1).
3. Peripheral blood eosinophil count. This was calcu-
lated from blood smear preparations.
4. Serum LDH was measured by the UV method.
5. Total IgE was measured by the radioimmunosorbent
test (RAST).
6. Antigen-specific IgE levels were also determined by
the RAST.
Statistical analysis
Data correlation was analyzed by the Spearman rank cor-
relation coefficient.
RESULTS
Patch testing of each antigen on the medial
aspect of the upper arm
After 24 h, the positivity rate for mite antigen was 6.5%.
Testing for other antigens was negative. After 48 h, the
positivity rates were 4.6% for house dust, 4.6% for mites,
3.1% for ragweed, 1.6% for kamogaya and 3.1% for
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Table 1 Atopic dermatitis severity scores
None Mild Moderate Severe
Face–Neck 0 1 2 3 A
Trunk 0 1 2 3 B
Extremities 0 1 2 3 C
Severity index = (A+B+C).
cedar. After 72 h, the positivity rates were 12.5% for
house dust, 15.6% for mites, 6.3% for ragweed, 10.9%
for kamogaya and 4.7% for cedar (Table 2). The results
in all control subjects were negative at all evaluation time
points. The positivity rates for each antigen (except mite
antigen) increased with time. The highest final rate was
15.6% for mite antigen and the lowest was 4.7% for
cedar antigen.
Patch testing at different sites
Patch testing was performed at two different sites (medial
aspects of the upper arm and thigh) in 12 AD patients.
These results are shown in Tables 3,4. Four patients
(patients 1, 2, 5 and 12) showed a positive response for
some antigen on both the upper arm and thigh. Two
patients (patients 3 and 11) with a positive response on
the upper arm had a negative or a questionably positive
(+?) response on the thigh. Six patients (patients 4, 6, 7,
8, 9 and 10) showed negative responses on both the
upper arm and thigh. None of the patients with a nega-
tive response on the upper arm showed a positive
response on the thigh. These results suggest that a posi-
tive patch test response is less easily obtained on the thigh
compared with the upper arm. In general, keratinization
of the thigh is greater than that of the upper arm. The
lower patch test positivity rate on the thigh seems to be
attributable to inhibition of antigen penetration by the
horny layer of the skin.
Clinical parameters
Clinical parameters such as severity index, duration of
disease, total serum IgE, LDH and eosinophil counts,
were recorded (data not shown).
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Table 2 Positive ratio in patch testing
Allergen Positive ratio (%; n = 64)
24 h 48 h 72 h
House dust (1%) 0 4.6 12.5
Dermatophagoides farinae (1%) 6.5 4.6 15.6
Ragweed (1%) 0 3.1 6.3
Kamogaya (5%) 0 1.6 10.9
Cedar (1%) 0 3.1 4.7
White Vaseline 0 0 0
White Vaseline containing 0.1% SLS 0 0 0
White Vaseline containing 0.1% SLS and 25% glycerine 0 0 0
SLS, sodium lauryl sulfate.
Table 3 Patch testing at different sites
Allergen
House dust Mites Cedar
Patient 1
Upper arm – + –
Thigh ND + ND
Patient 2
Upper arm + – –
Thigh + ND ND
Patient 3
Upper arm – – +
Thigh ND ND –
Patient 4
Upper arm – ND ND
Thigh – ND ND
Patient 5
Upper arm + ND ND
Thigh + ND ND
Patient 6
Upper arm – ND ND
Thigh – ND ND
Patient 7
Upper arm – ND ND
Thigh – ND ND
Patient 8
Upper arm – ND ND
Thigh – ND ND
Patient 9
Upper arm – ND ND
Thigh – ND ND
Patient 10
Upper arm – ND ND
Thigh – ND ND
Patient 11
Upper arm ND – +
Thigh ND ND +?
Patient 12
Upper arm – + –
Thigh ND + ND
ND, not done; +?, questionably positive.
Correlation of each parameter with the
results of patch testing
The present study found no significant correlation
between positive patch test results after 24, 48 and 72 h
for any single antigen (house dust, mites, ragweed,
kamogaya and cedar) and the corresponding antigen-
specific IgE level. We then combined the patch test results
for all antigens and evaluated the correlation between
the intensity of the patch test results for each antigen and
the corresponding antigen-specific IgE levels. Analysis of
the results at 72 h showed a significant correlation
between the intensity of the positive patch test responses
and specific IgE levels (P < 0.03; r = 0.35; Fig. 1).
Among these cases, specific IgE RAST levels were neg-
ative in two patients (3.1%) for house dust, in three
patients (4.7%) for mites, in two patients (3.1%) for
ragweed, in three patients (4.7%) for kamogaya and in
one patient (1.6%) for cedar.
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Table 4 Summation of patch testing results at different sites
No. responses (%)
Upper arm Thigh
Reactions
+ 6 (50) 4 (33.3)
+? 0 1
– 6 7
Total 12 12
Fig. 2 Correlation between patch test reactions (72 h) and
severity index (r = 0.44; P < 0.006).
Fig. 3 Correlation between patch test reactions (72 h) and
lactate dehydrogenase (LDH; r = 0.52; P < 0.002).
Fig. 4 Correlation between patch test reactions (72 h) and
total IgE (r = 0.56; P < 0.001).
Fig. 1 Correlation between patch test reactions (72 h) and
specific IgE levels (r = 0.35; P < 0.03). All antigen-specific IgE
levels (, house dust; , Dermatophagoides farinae; ×, Datylis
glomerata; +, Ambrosia artemisifolia; , Cryptomeria japon-
ica) and positive patch test results after 72 h are plotted on the
one graph.
Significant correlations were also found between the
intensity of positive patch test responses at 72 h and
severity index (P < 0.006; r = 0.44), LDH (P < 0.002; 
r = 0.52) and total IgE (P < 0.001; r = 0.56; Figs 2–4).
DISCUSSION
Much debate still exists regarding the role of allergic
reactions in the pathogenesis of AD. Proposed theories
concerning allergic pathogenesis can broadly be catego-
rized into those emphasizing the role of type I reactions
and those emphasizing the role of type IV reactions. The
reasons for emphasizing the involvement of type I allergic
reactions in AD include the high incidence of other atopic
disorders (e.g. allergic rhinitis and bronchial asthma), the
presence of high total serum IgE levels and the detection
of specific IgE antibodies to antigens in many AD
patients,2 elevated IgE levels in the skin, the binding of
IgE antibodies to Langerhans’ cells and mast cells and
binding of these cells with specific transepidermal inva-
sive antigens6 and the gradual recognition that pro-
longed inflammation is possible even in a type I allergic
response.11–13 The reasons for emphasizing the involve-
ment of type IV allergic reactions in AD include distinct
clinical and histopathologic similarities with allergic
contact dermatitis2 and the fact that, despite the reported
predominance of T helper (Th) 2 cells in AD, Th1 cells
may eventually predominate after a period of time.14–16
Patch testing has been used for a long time in the clini-
cal detection of skin allergens. Patch testing has also
been used for the evaluation of AD. In addition to mite
antigens, patch testing with human grime,17 cedar
pollen18,19 and Staphylococcus aureus20 has been
reported. However, the positivity rates and significance of
these results have varied. We have summarized the find-
ings from a number of previous studies regarding patch
testing for house dust and mites in Table 5.
As shown in Table 5,3,6,14,15,21–41 various types of mite
antigens have been used in previous studies. No spe-
cific antigen for standardized testing has been used. 
A variety of mite antigens has been used, including mite
scratch extract (Torii Pharmaceuticals),42 Dermatopha-
goides farinae (Df) crude antigen,4 Dermatophagoides
pteronyssinus (Dp) extract antigen21,22 and lyophilized
mite antigen.3 The concentrations of these preparations
also varies. Thus, patch test results with specific mite anti-
gens reported by one investigator often cannot be
confirmed by other investigators, which implies that they
have not been practical from a clinical standpoint.
Therefore, the present study was undertaken using patch
test reagents prepared from readily available allergen
extracts in Japan.
Kligman43 has described the use of sodium lauryl
sulfate (SLS) in conventional patch testing to increase the
transepidermal penetration of contact antigens, with an
optimal SLS concentration of 10%. However, irritant reac-
tions with 0.5% SLS have been reported.24 A comparison
study conducted by Yamamoto44 of various preparations
found that a concentration of 0.1% SLS was optimal for
demonstration of mite contact antigens in AD patients,
with a high positivity rate of 48%. We also compared dif-
ferent concentrations of SLS in 10 healthy volunteer
control subjects. Although 0.2% SLS caused irritation,
0.1% SLS did not. Therefore, we used a concentration of
0.1% SLS in the present study.
The allergen extracts we used contained a final glycerin
concentration of 25% (except for the house dust antigen).
However, 25% glycerine was confirmed to have no irritant
effect in the 10 healthy control subjects.
Many previous studies have reported pretreatment of
patch test sites by stripping or sandpaper abrasion.
However, such pretreatment can cause secretion of large
amounts of cytokines from keratinocytes.45 This may
lower the irritation threshold. Thus, optimum reagent
concentrations must be carefully evaluated in healthy
control subjects. Moreover, the skin of AD patients is
prone to irritation. Irritative stimuli that produce no
inflammation in healthy subjects may produce inflamma-
tion in patients with AD.3 Some previous reports have
described a positive response in control subjects and
some did not even mention the use of controls. Thus,
many studies may not be able to exclude the possibility of
irritation due to these other factors.
Considering potential problems, the protocol of the
present study does not contain any pretreatment pro-
cedures such as stripping. We performed patch testing
using reagents easily prepared from commercially avail-
able antigen extracts for diagnostic and therapeutic use.
These were mixed with white Vaseline containing 0.1%
SLS. Each antigen tested gave some positive responses.
In addition, the positivity rates increased in proportion
with the duration of antigen application. When patch
testing was performed on the medial aspects of the upper
arm and thigh in the same patients, the positivity rates on
the thigh (highly keratinized) seemed to be less than that
on the upper arm. Thus, we think the patch test results in
AD patients are related to the degree of keratinization at
the patch test site. Accordingly, our present data may
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have included several false-negative results. The findings
suggest that enhanced transepidermal antigen penetra-
tion may markedly increase the positivity rates. How-
ever, the previously mentioned pretreatment procedures
(e.g. stripping or sandpaper abrasion of the horny layer)
may cause inflammation due to factors other than an
immunologic mechanism. This may taint the original
purpose of patch testing. Our patch test method is
designed to improve selectivity, albeit at the expense of
some sensitivity.
The results of the present study show a correlation
between the intensity of patch test responses and antigen-
specific IgE levels. Specific IgE antibodies and antigens
cause type I allergic reactions with a wheal response,
which may be followed by a late phase reaction (LPR). 
In addition, the release of cytokines from mast cells
elicits the involvement of inflammatory cells, such as
eosinophils. Prolongation of this response can lead to
clinical manifestations of dermatitis. In general, an LPR
begins between 2 and several hours after intradermal
antigen injection, reaches maximum intensity by 6–12 h
and disappears after 24 h.46 In contrast with antigens
used in intradermal tests, the antigens used in patch tests
require a much longer time to penetrate the stratum
corneum and reach intradermal sites. These antigens
gradually penetrate the epidermis over a 48 h period and
activate IgE bound mast cells in the dermis. Subsequent
degranulation, an LPR and dermatitis can prolong the
observed response for up to 72 h. In addition to a corre-
lation with specific IgE levels, the positive patch test
responses in the present study also showed a correlation
with total IgE, LDH and severity index. A positive patch
test response in many cases of AD may represent a LPR
following a type I allergic response. However, positive
patch tests also develop in a small number of patients
with low levels of antigen-specific IgE. Thus, the role of
some other mechanism in addition to that of a type I
allergic reaction cannot be excluded. Atopic dermatitis is
caused or exaggerated by a variety of factors and has a
variable clinical presentation. Similarly, patch testing in
AD may also cause inflammation by more than one
mechanism.
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